Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia

References

• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Schena M, Larsson LG, Gottardi D, . Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992;79:2981–2989.
   PubMed Web of Science ®Google Scholar
• Collins RJ, Verschuer LA, Harmon BV, Prentice RL, Pope JH, Kerr JF. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol 1989;71:343–350.
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231–264.
   PubMed Web of Science ®Google Scholar
• Planelles L, Castillo-Gutierrez S, Medema JP, Morales-Luque A, Merle-Beral H, Hahne M. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 2007;92:1284–1285.
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, . Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785–798.
   PubMed Web of Science ®Google Scholar
• Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007;19:327–336.
   PubMed Web of Science ®Google Scholar
• Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol 2006;18:305–317.
   PubMed Web of Science ®Google Scholar
• Bojarska-Junak A, Hus I, Chocholska S, . BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res 2009;33: 1319–1327.
   PubMed Web of Science ®Google Scholar
• Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006;118:281–292.
   PubMed Web of Science ®Google Scholar
• Molica S, Digiesi G, Mauro F, . Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. Leuk Res 2009;33:162–165.
   PubMed Web of Science ®Google Scholar
• Novak AJ, Grote DM, Ziesmer SC, . Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006;24:2882–2888.
   Web of Science ®Google Scholar
• Molica S, Digiesi G, Battaglia C, . Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur J Haematol 2010;85:314–320.
   PubMed Web of Science ®Google Scholar
• Müller-Hermelink HK, Montserrat E, Catovsky D, . Chronic lymphocytic leukaemia/small lymphocytic lymphoma. Swerdlow HS, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. 180–182.
   Google Scholar
• Monzo M, Moreno I, Artells R, . Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients. Cancer Lett 2006;233: 117–123.
   PubMed Web of Science ®Google Scholar
• Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003;43:121–137.
   Web of Science ®Google Scholar
• Ferrer G, Hodgson K, Montserrat E, Moreno C. B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. Leuk Lymphoma 2009;50:1075–1082.
   PubMed Web of Science ®Google Scholar
• Endo T, Nishio M, Enzler T, . BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007;109:703–710.
   PubMed Web of Science ®Google Scholar
• Kern C, Cornuel JF, Billard C, . Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679–688.
   PubMed Web of Science ®Google Scholar
• Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002;100:2973–2979.
   PubMed Web of Science ®Google Scholar
• Sawicka-Powierza J, Jablonska E, Kloczko J, Piszcz J, Garley M, Ratajczk-Wrona W. Evaluation of TNF superfamily molecules release by neutrophils and B leukemic cells of patients with chronic B-cell lymphocytic leukemia. Neoplasma 2011;58:45–50.
   PubMed Web of Science ®Google Scholar
• Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367–3375.
   PubMed Web of Science ®Google Scholar
• Guadagnoli M, Kimberley F, Phan U, . Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood 2011 May 6. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Nishio M, Endo T, Tsukada N, . Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005;106:1012–1020.
   PubMed Web of Science ®Google Scholar
• Novak AJ, Grote DM, Stenson M, . Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004;104: 2247–2253.
   PubMed Web of Science ®Google Scholar